ALX Oncology Holdings Inc.
Every calculator, already run for ALXO
Open the full toolkit →You have the numbers on ALXO. Get the argument.
A written report on which of these readings actually decide the outcome for ALX Oncology Holdings Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering ALXOAnalyst Price Target Disagreement for ALX Oncology Holdings Inc.
Wall Street's bull case implies +253% from the current price; the bear case implies +135%. A 118% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ALXO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast ca…
ALXO — frequently asked
Is ALXO a buy right now?
Wall Street's consensus rating on ALX Oncology Holdings Inc. is none across 7 analysts, with a mean price target of $4.60 (+171% vs. the current $1.70). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ALXO's next earnings date?
ALX Oncology Holdings Inc. is next scheduled to report earnings around Nov 6, 2026. A full ALXO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for ALX Oncology Holdings Inc.?
Analysts covering ALX Oncology Holdings Inc. (ALXO) range from a bear-case target of $4.00 to a bull-case high of $6.00, with a mean consensus target of $4.60 across 5 analysts. The spread of $2.00 (118% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ALX Oncology Holdings Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ALX Oncology Holdings Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALXO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ALX Oncology Holdings Inc., in minutes. 3 free reports included with every account — no credit card required.